Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Holdings Increased by Fisher Asset Management LLC

Fisher Asset Management LLC increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 16.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 142,939 shares of the biotechnology company’s stock after purchasing an additional 20,679 shares during the quarter. Fisher Asset Management LLC owned approximately 0.11% of Arrowhead Pharmaceuticals worth $2,687,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $38,000. Van ECK Associates Corp boosted its position in Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares during the last quarter. KBC Group NV grew its stake in Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares in the last quarter. Quantbot Technologies LP acquired a new position in Arrowhead Pharmaceuticals in the 3rd quarter worth about $149,000. Finally, First Citizens Bank & Trust Co. purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $205,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Chardan Capital restated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. B. Riley restated a “buy” rating and set a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Royal Bank of Canada restated an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Sanford C. Bernstein decreased their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $41.44.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $17.35 on Thursday. The stock has a 50-day simple moving average of $19.51 and a 200 day simple moving average of $20.63. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $16.57 and a twelve month high of $35.80. The stock has a market capitalization of $2.19 billion, a PE ratio of -3.36 and a beta of 0.95. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 32,729 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the sale, the insider now directly owns 272,122 shares in the company, valued at approximately $5,393,458.04. The trade was a 10.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the company’s stock in a transaction on Friday, December 27th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. Following the completion of the transaction, the director now owns 36,740 shares of the company’s stock, valued at $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 280,765 shares of company stock valued at $5,227,313 in the last ninety days. Company insiders own 4.30% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.